Baricitinib Price and Manufacturing Company Overview 2024

Baricitinib (Baricitinib), trade name Olumiant, is a small molecule Janus kinase (JAK1/JAK2) inhibitor developed by Incyte Pharmaceuticals of the United States. This drug has a significant effect on the treatment of autoimmune diseases such as rheumatoid arthritis and alopecia areata. It effectively reduces inflammation and autoimmune reactions by regulating the JAK signaling pathway. Since 2009, Incyte has joined hands with Eli Lilly Pharmaceuticals, with Eli Lilly responsible for the global development and sales of the drug. Baricitinib has been approved for marketing in many countries and regions around the world, including the European Union, Japan, the United States and China.

EnterIn 2024, the price of baricitinib will fluctuate to a certain extent, affected by region, sales channels and specifications. In China, the price of 2mg*28 tablets of baricitinib (trade name: OLUMIANT) is generally between 1,000 and 2,000 yuan. This price range is affected by a variety of market factors, such as regional spending power, pricing policies of medical institutions or retail pharmacies, and market supply and demand conditions for drugs. It is worth noting that with the successive launch of generic drugs, the market price of baricitinib has shown a certain downward trend. For example, the price of the imitation version produced in Bangladesh is relatively affordable, with each box selling for between 200 and 800 to 900 yuan.

In terms of production companies, the original drug of baricitinib is developed by Incyte Pharmaceuticals in the United States, and the development and sales of the global market are handled by Eli Lilly Pharmaceuticals. For the Chinese market, currently available imported baricitinib products are produced by Eli Lilly and Company of the United States. At the same time, with the continuous development of the generic drug market, many pharmaceutical companies in Bangladesh, such as Yaopin International, Istar, Beacon, etc., have launched their own economical generic versions. These companies all have formal production qualifications, and the quality of their products has been recognized by the market.

In general,Although the price of baricitinib will fluctuate due to various market factors in 2024, the overall trend will remain stable or slightly downward. In the production process, original drugs and generic drugs coexist, providing patients with different needs with diverse choices.